Your session is about to expire
← Back to Search
Behavioral Intervention
Cognitive Behavioral Therapy for Parents of Children With Food Allergies
N/A
Recruiting
Led By Jessica Hellings, MD
Research Sponsored by University of Missouri, Kansas City
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Child must be aged 6-17 years with medically diagnosed serious food allergy(ies)
Meets cut-offs for anxiety and/or depression on the Hospital Anxiety and Depression Scale
Must not have
Using OTC anxiety or depression relief, or CBD or medical marijuana
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 weeks
Awards & highlights
No Placebo-Only Group
Summary
This trial will test if virtual CBT can help parents of kids with food allergies reduce anxiety, depression, and improve quality of life.
Who is the study for?
This trial is for parents over 18 with a child aged 6-17 who has a serious food allergy diagnosed by a doctor. Parents should show signs of anxiety or depression but can be on stable medication for these conditions. They must commit to weekly sessions and follow-ups without current psychiatric treatment changes, substance abuse, or use of certain over-the-counter remedies.
What is being tested?
The study tests if group Cognitive Behavioral Therapy (CBT) via virtual meetings helps reduce anxiety and depression in parents of children with food allergies. Participants are randomly placed into either the CBT group or a wait-list group to compare outcomes.
What are the potential side effects?
While CBT isn't typically associated with physical side effects, participants may experience emotional discomfort as they address personal issues during therapy sessions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My child, aged 6-17, has a serious food allergy diagnosed by a doctor.
Select...
My anxiety or depression scores are high based on a hospital test.
Select...
I am over 18 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I use over-the-counter remedies or CBD/medical marijuana for anxiety or depression.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 14 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 weeks
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Score of Food Allergy Quality of Life-Parent Burden Questionnaire (FAQL-PB)
Secondary study objectives
Change in Score of Hospital Anxiety and Depression Scale (HADS)
Change in Score of Pediatric Food Allergy Quality of Life Scale
Subject Satisfaction Questionnaire
Side effects data
From 2009 Phase 2 & 3 trial • 162 Patients • NCT0024861213%
suicidal ideation
4%
vertigo
4%
agitation/restlessness
4%
nausea
4%
depression
4%
anxiety
4%
profuse sweating
100%
80%
60%
40%
20%
0%
Study treatment Arm
Venlafaxine & CBT
Placebo & CBT
Venlafaxine & PMR
Placebo & PMR
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Virtual Cognitive Behavioral Therapy (CBT) groupExperimental Treatment1 Intervention
The Cognitive Behavioral Therapy (CBT) groups will be 6 weekly one-hour parent groups run by a Cognitive Behavioral Therapy (CBT) therapist according to a Cognitive Behavioral Therapy (CBT) manual focusing on anxiety and depression related to having a child with food allergies.
Group II: Waitlisted groupActive Control1 Intervention
The comparator groups will be waitlisted groups of parents of children with food allergies.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CBT
2013
Completed Phase 3
~4220
Find a Location
Who is running the clinical trial?
University of Missouri, Kansas CityLead Sponsor
71 Previous Clinical Trials
34,364 Total Patients Enrolled
Jessica Hellings, MDPrincipal InvestigatorUniversity of Missouri-Kansas City and University Health Behavioral Health
1 Previous Clinical Trials
18 Total Patients Enrolled
Stephen Jarvis, MDStudy ChairUniversity Health Behavioral Health, and UMKC
Share this study with friends
Copy Link
Messenger